Unaudited Results to 30 June 2023
24 July 2023
ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces the appointment of Niels Peter Bak (“Niels Peter”) as Technical Product Manager, effective from 1 September 2023.
Niels Peter has been brought on to the team as a pivotal part of executing the Company’s strategy to focus the business towards finished supplement dosage formats. In line with the Company’s defined strategic approach, Niels Peter will be heading up the product management function, with a specific focus on strengthening the infrastructure of ProBiotix, further accelerating product development and increasing the responsiveness to individual customer requirements. Niels Peter is a talented industry veteran with a proven track record in strategy execution, business to business product management, product development and technical marketing.
Niels Peter has almost 30 years’ experience in international roles in the global probiotics space across a number of well-known organisations. He was an integral part of the team at Bifodan A/S, where he specialised in product portfolio development and operational product management and was instrumental in bringing the company’s women’s health probiotic product line onto the market. Following the acquisition of Bifodan A/S by Deerland, he assumed a managerial role involving probiotic solutions. Prior to this, Niels Peter worked at global bioscience company, Chr. Hansen, in the probiotics division across a number of technical product and marketing roles from 1989 until 2006.
Steen Andersen, CEO of ProBiotix Health plc commented: “Niels Peter’s experience and track record of maintaining and expanding product portfolios to support growing sales, along with his network of industry contacts within the probiotics industry, will help us in our next phase of development. Niels Peter’s appointment comes at an opportune time, now that we have established international sales and brand awareness of our award winning LPLDL® probiotic ingredient and our CholBiome® finished format product line. His appointment will allow us to further capitalise on our efforts so far, as we increase our access to the European and North American markets.”
For further information, please contact:
|ProBiotix Health plc||https://probiotixhealth-ir.com/|
|Steen Andersen, Chief Executive||Contact via Walbrook below|
|Peterhouse Capital Ltd (AQSE Corporate Adviser and Broker)||Tel: 020 7469 0930|
|Walbrook PR Ltd||[email protected]|
|Anna Dunphy||Mob: 07876 741 001|
Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube